Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

Recruiting

Phase 3

Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral ActivityRibavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

Sponsor:

Ottawa Hospital Research Institute

Code:

NCT03759782

Conditions

Hepatitis B, Chronic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ribavirin

Tenofovir

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-04. This information was provided to ClinicalTrials.gov by Ottawa Hospital Research Institute on 2021-09-14.